Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00508963 |
Recruitment Status
:
Available
First Posted
: July 30, 2007
Last Update Posted
: December 15, 2014
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Leishmaniasis, Cutaneous Leishmaniasis, Mucocutaneous | Drug: sodium stibogluconate (Pentostam) |
Study Type : | Expanded Access |
Official Title: | Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis |

-
Drug: sodium stibogluconate (Pentostam)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Biopsy proven new world cutaneous or mucocutaneous leishmania
Exclusion Criteria:
- Prolonged QT
- Liver disease
- Pancreatitis

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00508963
Contact: Jane E Koehler, MA, MD | 415-476-3536 | jkoehler@medicine.ucsf.edu |
United States, California | |
University of CA at San Francisco Hospitals and Clinics | |
San Francisco, California, United States, 94143 |
Principal Investigator: | Brian Schwartz, MD | University of CA at San Francisco | |
Principal Investigator: | Kanade Shinkai, MD | University of CA at San Francisco |
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00508963 History of Changes |
Other Study ID Numbers: |
UCSF Infectious Diseases |
First Posted: | July 30, 2007 Key Record Dates |
Last Update Posted: | December 15, 2014 |
Last Verified: | December 2014 |
Keywords provided by University of California, San Francisco:
New World Cutaneous or Mucocutaneous Leishmaniasis |
Additional relevant MeSH terms:
Leishmaniasis Leishmaniasis, Cutaneous Leishmaniasis, Mucocutaneous Euglenozoa Infections Protozoan Infections Parasitic Diseases Skin Diseases, Parasitic Skin Diseases, Infectious |
Skin Diseases Antimony Sodium Gluconate Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Schistosomicides Antiplatyhelmintic Agents Anthelmintics |